论文部分内容阅读
目的:观察与评估静脉滴注埃索美拉唑钠治疗急性非静脉曲张性上消化道出血的临床疗效及安全性评价。方法:将我院收治的120例急性非静脉曲张性上消化道出血征象的患者,随机分为埃索美拉唑组(试验组)和奥美拉唑组(对照组),每组各60例。试验组给予埃索美拉唑钠静脉注射治疗,对照组给予奥美拉唑钠静脉注射治疗。对比2组患者24、72、120h的血细胞比容(PCV)和尿素氮(BUN)的平均值变化、临床疗效及不良反应。结果:2组患者24、72、120h的PCV和BUN平均值比较差异无统计学意义。试验组总有效率为95.41%,对照组总有效率为93.73%,2组患者疗效比较差异无统计学意义。试验组不良反应总发生率(8.33%)显著低于对照组(16.67%)(P<0.05)。结论:静脉给予埃索美拉唑钠治疗急性非静脉曲张性上消化道出血疗效与奥美拉唑钠相持平,但不良反应发生率更低,安全性较高,更适合于临床应用。
Objective: To observe and evaluate the clinical efficacy and safety evaluation of intravenous esomeprazole sodium in the treatment of acute non-variceal upper gastrointestinal bleeding. Methods: 120 patients with acute non-variceal upper gastrointestinal bleeding admitted to our hospital were randomly divided into esomeprazole group (experimental group) and omeprazole group (control group), each group 60 example. The experimental group was given esomeprazole sodium intravenous injection, while the control group was given omeprazole sodium intravenous injection. The mean changes of hematocrit (PCV) and blood urea nitrogen (BUN) at 24, 72 and 120 h were compared between the two groups. The clinical efficacy and adverse reactions were compared. Results: The mean PCV and BUN in two groups at 24, 72 and 120h had no significant difference. The total effective rate was 95.41% in the experimental group and 93.73% in the control group. There was no significant difference in the curative effect between the two groups. The total incidence of adverse reactions in the experimental group (8.33%) was significantly lower than that in the control group (16.67%) (P <0.05). Conclusion: Intravenous esomeprazole sodium in the treatment of acute non-variceal upper gastrointestinal bleeding and omeprazole sodium phase flat, but the incidence of adverse reactions lower, higher safety, more suitable for clinical application.